Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Telmisartan Intermediates With High Purity Telmisartan CAS 144701-48-4 Methyl 2-(p-Tolyl)benzoate CAS 114772-34-8 2-(p-Tolyl)benzoic Acid CAS 7148-03-0 Telmisartan Benzimidazole Acid CAS 152628-03-0 Telmisartan Methyl Ester CAS 528560-93-2 Methyl 2-[4-(Bromomethyl)phenyl]benzoate CAS 114772-38-2 Methyl 4-(Butyrylamino)-3-Methyl-5-Nitrobenzoate CAS 152628-01-8 2-n-Propyl-4-Methyl-6-(1-Methylbenzimidazole-2-yl)benzimidazole CAS 152628-02-9| Item | Specifications |
| Appearance | White Powder |
| Purity / Analysis Method | >99.0% (HPLC) |
| Loss on Drying | <1.00% |
| Residue on Ignition | <0.50% |
| Total Impurities | <1.00% |
| Heavy Metals (as Pb) | <20ppm |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Telmisartan (CAS: 144701-48-4) |
Description:
Specifications:
Package & Storage:
| Chemical Name | Methyl 4-(Butyrylamino)-3-Methyl-5-Nitrobenzoate |
| Synonyms | Telmisartan Impurity 31; 3-Methyl-4-Butyrylamido-5-Nitro Benzoic Acid Methyl Ester; 4-Butyrylamino-3-methyl-5-nitrobenzoic Acid Methyl Ester |
| CAS Number | 152628-01-8 |
| CAT Number | RF-PI1881 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C13H16N2O5 |
| Molecular Weight | 280.28 |
| Melting Point | 151.0~153.0℃ |
| Density | 1.265 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Methyl 4-(Butyrylamino)-3-Methyl-5-Nitrobenzoate (CAS: 152628-01-8) is a useful synthetic intermediate in the production of Telmisartan (CAS: 144701-48-4), an antihypertensive drug. Methyl 4-(Butyrylamino)-3-Methyl-5-Nitrobenzoate is part of a more efficient process of synthesizing Telmisartan in terms of impurity, yield, cost, and large-scale production. Telmisartan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors.
